We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.88 | -0.68% | 127.92 | 129.76 | 127.985 | 129.76 | 7,446,078 | 01:00:00 |
By Colin Kellaher
Merck & Co. on Thursday said a pivotal Phase 3 study of its blockbuster cancer drug Keytruda met a second primary endpoint of event-free survival in patients with high-risk early-stage triple-negative breast cancer.
The Kenilworth, N.J., drugmaker said Keytruda in combination with chemotherapy before surgery and continuing as a single agent after surgery showed statistically significant improvement in event-free survival versus pre-operative chemotherapy.
Merck, which previously reported that the study had met its other dual primary endpoint of pathological complete response, said Keytruda is the first anti-PD-1 therapy to show a statistically significant improvement in event-free survival as a neoadjuvant and adjuvant therapy for patients with triple-negative breast cancer, an aggressive cancer that characteristically has a high recurrence rate within the first five years after diagnosis.
The U.S. Food and Drug Administration in March turned away Merck's application for expanded approval of Keytruda for patients with high-risk early-stage triple-negative breast cancer based on the pCR data and early interim event-free survival findings. The agency was following advice from an advisory committee that recommended a regulatory decision on the indication should be deferred until further data were available from the study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2021 07:27 ET (11:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions